

Table 1: Clinic attendance by prioritised ethnicity.

	European n=199 (41.8%)	Māori n=46 (9.5%)	Pacific peoples n=73 (13.9%)	Asian n=147 (32.7%)	Middle Eastern/Latin American/ African n=9 (2.1%)
Clinic attended— no./total no. (%)	162/199 (81.4)	37/46 (80.4)	54/73 (74.0)	127/147 (86.4)	8/9 (88.9)
Time to review— mean days +/- SD	266 ± 396	282 ± 494	275 ± 399	211 ± 760	217 ± 179
Reason for clinic non-attendance—no./total no. (%)					
Deceased	6/199 (3.0)	1/46 (2.2)	2/73 (2.7)	2/147 (1.4)	0/9 (0)
Missed appointments	18/199 (9.0)	7/46 (15.2)	11/73 (15.1)	11/147 (7.5)	0/9 (0)
Direct to cataract surgery	2/199 (1.0)	0/46 (0)	1/73 (1.4)	0/147 (0)	0/9 (0)
Direct to laser	0/199 (0)	1/46 (2.2)	1/73 (1.4)	0/147 (0)	0/9 (0)
Virtual clinic	1/199 (0.5)	0/46 (0)	0/73 (0)	1/147 (0.7)	0/9 (0)
No clinic booked	10/199 (5.0)	0/46 (0)	4/73 (5.5)	6/147 (4.1)	1/9 (11.1)

Table 2: Patient demographics at presentation to clinic.

	European n=162 (42%)	Māori n=37 (9.5%)	Pacific peoples n=54 (13.9%)	Asian n=127 (32.7%)	Middle Eastern/ Latin American/ African n=8 (2%)	P-value
Male—no./total no. (%)	98/162 (60.5)	24/37 (64.9)	27/54 (50.0)	78/127 (61.4)	6/8 (75.0)	0.480
Age—years +/- SD	57.7 ± 18.1	54.5 ± 12.2	53.5 ± 14.8	58.5 ± 13.0	58.9 ± 6.5	0.260
Type 2 diabetes mellitus—no./total no. recorded (%)	59/108 (54.6)	23/26 (88.5)	33/39 (84.6)	92/97 (94.8)	5/5 (100)	<0.001
Duration of diabetes—mean years ± SD	16.7 ± 10.9	11.2 ± 6.9	11.8 ± 6.5	12.1 ± 8.4	7.3 ± 2.5	0.063
HbA _{1c} (mmol/mol)—mean ± SD	65.1 ± 18.6	74.1 ± 17.8	80.3 ± 20.2	65.9 ± 20.1	63.5 ± 12.2	0.001
Vision (LogMAR)—mean ± SD	0.17 ± 0.29	0.24 ± 0.41	0.20 ± 0.27	0.20 ± 0.37	0.08 ± 0.12	0.720
Proliferative DR—no./total no. (%)	10/162 (6.2)	6/37 (16.2)	5/54 (9.3)	9/127 (7.1)	1/8 (12.5)	0.329
DMO—no./total no. recorded (%)	40/133 (30.1)	12/25 (48.0)	12/43 (27.9)	30/106 (28.3)	1/7 (14.3)	0.264

Table 3: Documentation of history, examination and investigations by prioritised ethnicity.

	European (n=162)	Māori (n=37)	Pacific peoples (n=54)	Asian (n=127)	Middle Eastern/ Latin American/ African (n=8)	P-value
History score—mean +/- SD	1.4 ± 1.1	1.7 ± 1.0	1.8 ± 1.0	1.8 ± 1.1	1.8 ± 1.0	0.809
Examination score—mean +/- SD	4.2 ± 0.7	4.2 ± 0.7	4.4 ± 0.7	4.3 ± 0.8	4.2 ± 0.7	0.513
Investigation score—mean +/- SD	1.4 ± 0.6	1.5 ± 0.6	1.7 ± 0.6	1.4 ± 0.7	1.5 ± 0.6	0.623
Total score out of 10—mean +/- SD	7.0 ± 1.7	7.2 ± 1.4	7.4 ± 1.6	7.1 ± 1.9	7.5 ± 0.9	0.701

Table 4: Treatment decisions by prioritised ethnicity.

Treatments provided	European (n=162)	Māori (n=37)	Pacific peoples (n=54)	Asian (n=127)	Middle Eastern/ Latin American/ African (n=8)	P-value
If female aged 20–40 discussed pregnancy plans—no./no. eligible (%)	1/14 (7.1)	1/4 (25.0)	1/4 (25.0)	0/0	0/1 (0)	0.662
If significant cataract CPAC performed—no./no. eligible (%)	4/10 (40.0)	2/4 (50.0)	3/7 (60.0)	4/5 (42.9)	0/0 (0)	0.759
If DMO with vision 6/9 or worse anti-VEGF started—no./no. eligible (%)	9/19 (47.4)	2/10 (20.0)	3/6 (50.0)	5/14 (35.7)	0/1 (0)	0.542
Same day laser for PDR—no./no. eligible (%)	9/10 (90.0)	5/6 (83.3)	6/7 (85.7)	10/10 (100.0)	0/0 (0)	0.647
Urgent diabetic nurse referral if HbA _{1c} >100mmol/mol—no./no. eligible (%)	3/6 (33.3)	1/3 (33.3)	1/6 (16.7)	0/5 (0)	0/0 (0)	0.514
Discussed improving diabetic control if HbA _{1c} >58mmol/mol—no./no. eligible (%)	7/49 (14.3)	5/20 (25.0)	8/29 (27.6)	7/44 (15.9)	1/3 (33.3)	0.527
Laser for non-foveal CSMO—no./no. eligible (%)	6/19 (31.6)	4/7 (57.1)	2/4 (50.0)	7/13 (53.8)	0/0	0.523
Letter copied to patient—no./total no. (%)	116/162 (71.6)	25/37 (67.6)	33/54 (61.1)	91/127 (71.7)	7/8 (87.5)	0.285
Total treatment score—mean +/- SD	1.0 ± 0.7	1.3 ± 1.1	1.1 ± 1.1	1.0 ± 0.7	1.0 ± 0.5	0.169
Treatment denominator—mean +/- SD	1.8 ± 0.9	2.6 ± 1.3	2.2 ± 1.2	1.8 ± 1.0	1.5 ± 0.8	0.001
Treatment percentage—mean +/- SD	49.2 ± 40.3	42.8 ± 25.2	50.4 ± 41.2	54.4 ± 38.4	58.3 ± 50.0	0.788